21 CFR Part 11 and cGMP don't mention penetration testing but the controls they require depend on it. Learn how to align your pharma pen test program with regulatory requirements and prepare for FDA data integrity inspections.

Nation-state actors treat pharma like critical infrastructure targeting formulation data, synthesis routes, and clinical IP with patience and precision. Learn why standard pen testing misses this threat and what adversary simulation reveals instead.

R&D and GxP regulated environments have different risk profiles, compliance requirements, and testing constraints. Learn why a single unified pen test scope fails both and how to run dual-scope engagements efficiently.

Semiconductor manufacturers face dual compliance obligations under CMMC 2.0 and the CHIPS Act and a standard pen test satisfies neither fully. Learn how to build a unified program that covers both frameworks.

Completing a pen test isn't enough for CMMC. Learn what C3PAO assessors actually look for in your evidence package and how to align your report, scope, POA&M, and remediation docs to specific practice statements.